U.S., April 26 -- ClinicalTrials.gov registry received information related to the study (NCT06944444) titled 'A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors' on April 10.
Brief Summary: This study was an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSS59 as a single agent in patients with advanced malignancies.
Study Start Date: May 10
Study Type: INTERVENTIONAL
Condition:
Malignant Tumors
Intervention:
DRUG: SSS59
A humanized antibody targeting MUC17
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Disclaimer: Curated by HT Syndication....